Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation.

Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia. Cancer Cell (2016) 1.44

The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer (2016) 1.00

Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes. Oncotarget (2016) 0.79

RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications. Haematologica (2016) 0.79

The genetics and molecular biology of T-ALL. Blood (2017) 0.78

The origin of relapse in pediatric T-cell acute lymphoblastic leukemia. Haematologica (2015) 0.77

Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing. Oncotarget (2016) 0.76

Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia. Blood Cancer J (2017) 0.75

Oligomeric interface modulation causes misregulation of purine 5´-nucleotidase in relapsed leukemia. BMC Biol (2016) 0.75

Cohesin Mutations in Myeloid Malignancies. Trends Cancer (2017) 0.75

A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53

Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33

Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25

Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55

Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics (2009) 6.08

A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics (2012) 4.95

FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59

The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med (2007) 4.04

Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet (2007) 3.48

The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43

Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood (2011) 3.30

Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood (2000) 3.13

Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia (2008) 3.10

The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood (2007) 2.99

Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med (2012) 2.86

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood (2008) 2.68

Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med (2013) 2.67

PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66

Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet (2013) 2.38

Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87. J Clin Oncol (2005) 2.36

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood (2011) 2.18

Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood (2006) 2.10

Enhanced tumor formation in mice heterozygous for Blm mutation. Science (2002) 2.07

Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med (2011) 2.04

BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03

Comprehensive analysis of DNA methylation data with RnBeads. Nat Methods (2014) 2.03

Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A (2013) 2.00

The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun (2014) 1.90

Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat Genet (2013) 1.77

WT1 mutations in T-ALL. Blood (2009) 1.75

Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood (2006) 1.74

Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Clin Oncol (2011) 1.71

Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 1.68

Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood (2011) 1.67

Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia. Genome Biol (2013) 1.57

Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol (2008) 1.50

Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun (2015) 1.49

Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood (2010) 1.40

High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood (2011) 1.22

The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. Haematologica (2012) 1.18

Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia (2013) 1.17

Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia (2008) 1.08

Identification of chromatin remodeling genes Arid4a and Arid4b as leukemia suppressor genes. J Natl Cancer Inst (2008) 1.05

Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. Leukemia (2012) 0.99

Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood (1995) 0.90

Clinical and genetic findings in an Ashkenazi Jewish population with colorectal neoplasms. Cancer (2005) 0.88

Long-term results of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98. Leukemia (2009) 0.86

Very early/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment. Leukemia (2011) 0.84

Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia. Leukemia (2014) 0.78

The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. Haematologica (2014) 1.00